Cefpimizole (CAS 84880-03-5) Suppliers and Product Information

Cefpimizole is a semisynthetic parenteral cephalosporin with modest activity compared to other antipseudomonal cephalosporins. It was developed by Ajinomoto in Japan and is also known by brand names Ajicef and Renilan. Cefpimizole exhibits a spectrum of activity somewhat narrower than cefotaxime and cefoperazone.

Like cefoperazone, cefpimizole is susceptible to many enterobacterial β-lactamases. In pharmacokinetic studies, volunteers receiving 0.1-1 g intramuscularly showed mean peak plasma concentrations of 15-20 and 35-40 mg/L respectively. The plasma elimination half-life is 1.8-2.1 h, with 70-80% being recovered unchanged in the urine.

Cefpimizole is no longer widely available, and significant pain at the site of injection has been reported as a prominent adverse event.

Frequently Asked Questions about Cefpimizole

Q: What is the primary use of Cefpimizole?

A: Cefpimizole is primarily used as an antibacterial agent. It is a third-generation cephalosporin antibiotic used to treat various bacterial infections.

Q: How is Cefpimizole administered?

A: Cefpimizole is administered parenterally, typically through intramuscular injection.

Q: What is the typical purity of Cefpimizole available from suppliers?

A: The purity of Cefpimizole from suppliers typically ranges from ≥98% to 99.9%, depending on the manufacturer and intended use.

Q: Is Cefpimizole still widely used in clinical practice?

A: No, Cefpimizole is no longer widely available or used in clinical practice. This is partly due to the development of more effective antibiotics and the reported adverse event of significant pain at the injection site.